Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | RAD52 | P43351 | 1/20 | 0.64 |
| ▸ | GFER | P55789 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 6/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.57 |
| ▸ | APP | P05067 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362771 | 0.85 | MAPT (1.00) | MAPTGAAATMRAD52GFER | |
| SCHEMBL9452123 | 0.85 | MAPT (0.74) | MAPTGAAATMRAD52GFER | |
| SCHEMBL2012878 | 0.85 | MAPT (1.00) | MAPTGAAATMRAD52GFER | |
| SCHEMBL5309628 | 0.85 | MAPT (0.74) | MAPTGAAATMRAD52GFER | |
| SCHEMBL21346893 | 0.85 | MAPT (0.74) | MAPTGAAATMRAD52GFER | |
| SCHEMBL21121632 | 0.85 | MAPT (0.69) | MAPTGAAATMRAD52GFER | |
| SCHEMBL5311243 | 0.82 | CYP2D6 (0.65) | MAPTGAAATMRAD52GFER | |
| SCHEMBL4751730 | 0.82 | MAPT (0.70) | MAPTGAAATMRAD52GFER | |
| SCHEMBL12672223 | 0.82 | MAPKAPK2 (0.53) | MAPTGAAATMRAD52GFER | |
| Metaquine SCHEMBL7205743 | 0.82 | FADS1 (0.71) | MAPTGAAATMRAD52GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481806-B1 | 4-ANILINO-QUINOLINE COMPOUNDS AS ANTI-CANCER AGENTS | INST NAT SANTE RECH MED (FR) | 2023-06-07 | — | — | EP | claimed |
| EP-3735407-A1 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2020-11-11 | — | — | EP | claimed |
| WO-2019134969-A1 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-07-11 | — | — | WO | claimed |
| EP-3735407-A1 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2020-11-11 | — | — | EP | disclosed |
| WO-2019134969-A1 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-07-11 | — | — | WO | disclosed |
| US-8288549-B2 | Glycine B antagonist | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110190342-A1 | GLYCINE B ANTAGONIST | HENRICH MARKUS | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190342-A1 | GLYCINE B ANTAGONIST | GRIN2B, GLRB, GRIN2A | MAPT 1267/4885GAA 707/4885ATM 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.